Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia

Journal of Clinical Psychopharmacology

Volumn 28, Issue 7 SUPPL. 1, 2008, Pages

  Kane, John M ^a   Lauriello, John ^b   Laska, Eugene ^c   Di Marino, Michael ^d   Wolfgang, Curt D ^d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Vanda Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; ILOPERIDONE;

ADULT; AGED; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BRADYKINESIA; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HEADACHE; HUMAN; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE RIGIDITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALOPERIDOL; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PIPERIDINES; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 40849114977     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318169cca7     Document Type: Article

References (30)

1. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141.
2. Seeman MV. Symptoms of schizophrenia: normal adaptations to inability. Med Hypotheses. 2007;69:253-257.
3. Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry. 2004;65:8-9.
4. Goldman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999;60(suppl 21):10-15.
5. Green AI, Canuso CM, Brenner MJ, et al. Detection and management of comorbidity in patients with schizophrenia. Psychiatr Clin North Am. 2003;26:115-139.
6. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.
7. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull. 1995;21:419-429.
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
9. Mossman D, Lehrer DS. Conventional and atypical antipsychotics and the evolving standard of care. Psychiatr Serv. 2000;51:1528-1535.
10. Csernansky JG, Schuchart EK. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics. CNS Drugs. 2002;16:473-484.
11. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006;14:152-164.
12. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
13. Weiden PJ. Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68(suppl 1):12-19.
14. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:553-560.
15. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68:29-39.
16. Kalkman HO, Feuerbach D, Lotscher E, et al. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003;73:1151-1159.
17. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001;25:904-914.
18. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76:247-265.
19. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
20. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
21. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008;28:S4-S11.
22. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol. 2008;28:S12-S19.
23. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008;28:S20-S28.
24. Guidance for Industry: E10 Choice of Control Group and Related Issues in Clinical Trials. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2001.
25. Eklund K, Forsman A. Minimal effective dose and relapse-double-blind trial: haloperidol decanoate vs. placebo. Clin Neuropharmacol. 1991;14(suppl 2):S7-S12.
26. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. J Psychiatr Res. 1998;32:243-250.
27. Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 2006;189:259-266.
28. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17:207-215.
29. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med. 2005;118(suppl 2):15S-22S.
30. Haupt DW. Differential metabolic effects of antipsychotic treatments. Eur Neuropsychopharmacol. 2006;16(suppl 3):S149-S155.